GAPDH antibody (AA 3-335)

Catalog No. ABIN7153644

The Mouse Monoclonal anti-GAPDH antibody is suitable to detect GAPDH in samples from Human. It has been validated for WB, IHC, ELISA, IF, IP and FACS.

Quick Overview for GAPDH antibody (AA 3-335) (ABIN7153644)

Target: GAPDH (Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This GAPDH antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (IHC), ELISA, Immunofluorescence (IF), Immunoprecipitation (IP), Flow Cytometry (FACS)

Clone: 14C2F11

Product Details anti-GAPDH Antibody

Binding Specificity: AA 3-335

Cross-Reactivity: Human, Rabbit, Rat

Purification: Protein G purified

Immunogen: Recombinant Human GAPDH protein (3-335AA)

Isotype: IgG1, IgG1 kappa

Application Details

Application Notes: Recommended dilution: WB:1:5000-1:1600000, IHC:1:50-1:500, IF:1:50-1:200, IP:1 μL-2 μL, FC:1:100-1:300,

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, PH 7.4

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C,-80 °C

Storage Comment: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Target Details for GAPDH

Target: GAPDH (Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH))

Alternative Name: GAPDH

Background:

Background: Glyceraldehyde 3-phosphate dehydrogenase (GAPDH or G3PDH) is an enzyme of 37 kDa that is consisdered as a cellular enzyme involved in glycolysis. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is a pleiotropic enzyme that is overexpressed in apoptosis and in several human chronic pathologies. Its role as a mediator for cell death has also been highlighted. At the molecular level, sequential steps lead to nuclear translocation of GAPDH during cell death as follows: first, a catalytic cysteine in GAPDH (C150 in rat GAPDH) is S-nitrosylated by nitric oxide (NO) that is generated from inducible nitric oxide synthase (iNOS) and/or neuronal NOS (nNOS), second, the modified GAPDH becomes capable of binding with Siah1, an E3 ubiquitin ligase, and stabilizes it, third, the GAPDH-Siah protein complex translocates to the nucleus, dependent on Siah1's nuclear localization signal, and degrades Siah1's substrates in the nucleus, which results in cytotoxicity. A recent report suggests that GAPDH may be genetically associated with late-onset of Alzheimer's disease.-deprenyl, which has originally been used as a monoamine oxidase inhibitor for Parkinson's disease, binds to GAPDH and displays neuroprotective actions.

Aliases: GAPDH, G3PD, GAPD, MGC88685

UniProt: P04406